JMP Securities Sticks to Its Hold Rating for Vertex Pharmaceuticals

By Jason Carr

JMP Securities analyst Liisa Bayko reiterated a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today and set a price target of $211. The company’s shares opened today at $151.40.

According to, Bayko is a 5-star analyst with an average return of 17.8% and a 48.8% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, DBV Technologies SA – American, and Arbutus Biopharma Corporation.

Currently, the analyst consensus on Vertex Pharmaceuticals is Strong Buy and the average price target is $192, representing a 26.8% upside.

In a report issued on February 1, H.C. Wainwright also assigned a Hold rating to the stock with a $103 price target.

Based on Vertex Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $652 million and quarterly net profit of $101 million. In comparison, last year the company earned revenue of $459 million and had a net profit of $32.95 million.

Based on the recent corporate insider activity of 123 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.